A Randomized, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986171 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 26 May 2017
At a glance
- Drugs BMS 986171 (Primary)
- Indications Hepatic fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions
- Sponsors Bristol-Myers Squibb
- 22 May 2017 Status changed from active, no longer recruiting to completed.
- 03 Jan 2017 Planned End Date changed to 1 Jan 2017.
- 03 Jan 2017 Status changed from completed to active, no longer recruiting.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History